# IGF-1 Therapy in Patients With Cystic Fibrosis

> **NCT00566241** · PHASE1 · TERMINATED · sponsor: **Stony Brook University** · enrollment: 15 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** recombinant human IGF-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00566241
- **Lead sponsor:** Stony Brook University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2013-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566241, "IGF-1 Therapy in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00566241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*